NEUROTECH INTERNATIONAL LIMITED - Announcements

Market Cap $57.99M Add to my watchlist

Healthcare Medical Devices

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Combining science, nature and human compassion, Little Green Pharma (ASX:LGP) are committed to improving the quality of life for sufferers of debilitating chronic conditions. NEWS: Little Green Pharma shares surge as Germany legalises Cannabis.

Announcements

Filter Results

All Price Sensitive Only

NTI	NTI Formalises Strategic Partnership with Fenix Innovation		03/06/24	146.77KB	Share
NTI	Notice of Change of Auditor		08/05/24	83.71KB	Share
NTI	Change of Director's Interest Notice		08/05/24	1.08MB	Share
NTI	Investor Webinar on Rett Syndrome Clinical Trial Results		06/05/24	85.16KB	Share
NTI	Investor Presentation		06/05/24	1.77MB	Share
NTI	Rett Syndrome Phase I/II trial shows significant benefits	PRICE SENSITIVE	06/05/24	593.85KB	Share
NTI	Trading Halt	PRICE SENSITIVE	03/05/24	140.26KB	Share
NTI	Neurotech Receives $10 Million in Placement Funds		24/04/24	83.91KB	Share
NTI	Notification regarding unquoted securities - NTI		24/04/24	17.64KB	Share
NTI	Secondary Trading Notice		24/04/24	91.73KB	Share
NTI	Application for quotation of securities - NTI		24/04/24	15.81KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/04/24	445.81KB	Share
NTI	Initial Director's Interest Notice		19/04/24	125.34KB	Share
NTI	Final Director's Interest Notice		19/04/24	130.37KB	Share
NTI	Proposed issue of securities - NTI		19/04/24	16.84KB	Share
NTI	Board Changes		19/04/24	102.61KB	Share
NTI	Investor Presentation		17/04/24	2.32MB	Share
NTI	Proposed issue of securities - NTI		17/04/24	18.84KB	Share
NTI	Neurotech Completes $10 Million Capital Raise	PRICE SENSITIVE	17/04/24	193.4KB	Share
NTI	Positive Top-Line Rett Syndrome Clinical Trial Results	PRICE SENSITIVE	17/04/24	200.12KB	Share
NTI	Phase II/III ASD Trial Successfully Meets Primary Endpoint	PRICE SENSITIVE	17/04/24	361.07KB	Share
NTI	Investor Webinar on Clinical Trial Results		16/04/24	98.91KB	Share
NTI	Trading Halt	PRICE SENSITIVE	15/04/24	141.44KB	Share
NTI	Proposed issue of securities - NTI		10/04/24	19.39KB	Share
NTI	Strategic Partnership with Fenix Innovation Group		10/04/24	196.39KB	Share
NTI	Last Patient Completes Treatment in NTIASD2 Clinical Trial	PRICE SENSITIVE	10/04/24	183.31KB	Share
NTI	Change in substantial holding		27/03/24	289.69KB	Share
NTI	Appointment of Joint Company Secretary		21/03/24	76.78KB	Share
NTI	Neurotech Presentation at NWR Virtual Healthcare Conference		21/03/24	2.52MB	Share
NTI	Neurotech to present at NWR Virtual Healthcare Conference		19/03/24	98.59KB	Share
NTI	Secondary Trading Notice		15/03/24	91.99KB	Share
NTI	Notification regarding unquoted securities - NTI		15/03/24	14.66KB	Share
NTI	Application for quotation of securities - NTI		15/03/24	15.68KB	Share
NTI	NTI to Present at Spark Plus Conference in Singapore		13/03/24	2.59MB	Share
NTI	Rett Syndrome Patients to Receive NTI164 for 52 Weeks	PRICE SENSITIVE	13/03/24	180.94KB	Share
NTI	Notification of cessation of securities - NTI		12/03/24	14.65KB	Share
NTI	Secondary Trading Notice		11/03/24	91.98KB	Share
NTI	Notification regarding unquoted securities - NTI		08/03/24	14.99KB	Share
NTI	Application for quotation of securities - NTI		08/03/24	15.9KB	Share
NTI	Initial ESG Report		27/02/24	1.8MB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	27/02/24	814.41KB	Share
NTI	Investor Presentation		21/02/24	2.39MB	Share
NTI	PANDAS/PANS Patients Show Continued Clinical Improvement	PRICE SENSITIVE	21/02/24	325.1KB	Share
NTI	Secondary Trading Notice		14/02/24	93.56KB	Share
NTI	Notification regarding unquoted securities - NTI		14/02/24	14.99KB	Share
NTI	Application for quotation of securities - NTI		14/02/24	15.91KB	Share
NTI	Neurotech Receives Additional HREC Approval in Autism	PRICE SENSITIVE	13/02/24	114.1KB	Share
NTI	ASD Phase I/II Patients Exceed Treatment Beyond 90 Weeks		07/02/24	130.25KB	Share
NTI	Amended Change of Director's Interest Notice		30/01/24	233.81KB	Share
NTI	Change of Director's Interest Notice		30/01/24	150.24KB	Share
NTI	NTI Receives HREC Approval for Cerebral Palsy Trial	PRICE SENSITIVE	29/01/24	179.92KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/01/24	583.12KB	Share
NTI	Secondary Trading Notice		22/01/24	91.57KB	Share
NTI	Application for quotation of securities - NTI		22/01/24	25.64KB	Share
NTI	Notification regarding unquoted securities - NTI		17/01/24	28.33KB	Share
NTI	Secondary Trading Notice		19/12/23	91.77KB	Share
NTI	Application for quotation of securities - NTI		19/12/23	24.91KB	Share
NTI	Phase II/III Autism Clinical Trial Completes Recruitment	PRICE SENSITIVE	19/12/23	178.77KB	Share
NTI	Change in substantial holding		05/12/23	291.25KB	Share
NTI	HREC Approval to Extend Phase II/III ASD Trial to Adults	PRICE SENSITIVE	04/12/23	175.52KB	Share
NTI	Change of Director's Interest Notice x 2		01/12/23	329.86KB	Share
NTI	Application for quotation of securities - NTI		30/11/23	24.93KB	Share
NTI	Investor Presentation		22/11/23	2.34MB	Share
NTI	New Constitution		15/11/23	603.29KB	Share
NTI	Results of Meeting		15/11/23	103.44KB	Share
NTI	2023 Annual General Meeting Presentation		15/11/23	1.89MB	Share
NTI	Chairman's Address to 2023 Annual General Meeting		15/11/23	111.09KB	Share
NTI	Neurotech Receives $3.17 Million R&D Tax Incentive Refund	PRICE SENSITIVE	14/11/23	105.98KB	Share
NTI	Q&A on Phase I/II PANDAS/PANS Clinical Trial Results		01/11/23	169.14KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/23	396.35KB	Share
NTI	Notice of Quarterly Investor Conference Call		24/10/23	101.25KB	Share
NTI	Notice of Annual General Meeting/Proxy Form		16/10/23	626.33KB	Share
NTI	Investor Presentation - PANDAS/PANS Clinical Trials Results		06/10/23	1.58MB	Share
NTI	Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint	PRICE SENSITIVE	06/10/23	202.18KB	Share
NTI	Trading Halt	PRICE SENSITIVE	04/10/23	503.7KB	Share
NTI	Completion of Patient Recruitment in NTIRTT1 Clinical Trial	PRICE SENSITIVE	26/09/23	186.34KB	Share
NTI	Annual Report (Typeset)		22/09/23	6.67MB	Share
NTI	Secondary Trading Notice		18/09/23	93.51KB	Share
NTI	Application for quotation of securities - NTI		18/09/23	25.51KB	Share
NTI	Proposed issue of securities - NTI		15/09/23	24.56KB	Share
NTI	Clinician Briefing Presentation and Webcast		15/09/23	1.78MB	Share
NTI	Proposed issue of securities - NTI		15/09/23	31.63KB	Share
NTI	Appointment of Corporate Advisor		15/09/23	93.81KB	Share
NTI	Upcoming Clinician Briefing		11/09/23	161.9KB	Share
NTI	Last Patient Completes Treatment in NTIPANS1 Clinical Trial	PRICE SENSITIVE	31/08/23	141.88KB	Share
NTI	Appendix 4G and Corporate Governance Statement		30/08/23	375.23KB	Share
NTI	Appendix 4E & Annual Report	PRICE SENSITIVE	30/08/23	1.16MB	Share
NTI	Application for quotation of securities - NTI		08/08/23	24.86KB	Share
NTI	Proposed issue of securities - NTI		04/08/23	24.68KB	Share
NTI	Disclosure Document		04/08/23	310.97KB	Share
NTI	First Patient Treated in Rett Syndrome Clinical Trial	PRICE SENSITIVE	01/08/23	181.29KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/07/23	321.97KB	Share
NTI	Notice of Quarterly Investor Conference Call		19/07/23	138.69KB	Share
NTI	NTI Receives HREC Approval for Rett Syndrome Clinical Trial	PRICE SENSITIVE	10/07/23	213.2KB	Share
NTI	Notification of cessation of securities - NTI		30/06/23	22.47KB	Share
NTI	Notification regarding unquoted securities - NTI		28/06/23	43.13KB	Share
NTI	NTI to Present at Rett Syndrome Foundation Meeting		05/06/23	120.49KB	Share
NTI	Results of Meeting		01/06/23	102.52KB	Share
NTI	NTI Granted 2 Year Extension of Treatment for ASD Patients	PRICE SENSITIVE	31/05/23	188.33KB	Share
NTI	NTI granted HREC Approval for PANDAS/PANS Trial Extension	PRICE SENSITIVE	30/05/23	178.8KB	Share

NTI NTI Formalises Strategic Partnership with Fenix Innovation
03/06/24		146.77KB	Share
NTI Notice of Change of Auditor
08/05/24		83.71KB	Share
NTI Change of Director's Interest Notice
08/05/24		1.08MB	Share
NTI Investor Webinar on Rett Syndrome Clinical Trial Results
06/05/24		85.16KB	Share
NTI Investor Presentation
06/05/24		1.77MB	Share
NTI Rett Syndrome Phase I/II trial shows significant benefits
06/05/24	PRICE SENSITIVE	593.85KB	Share
NTI Trading Halt
03/05/24	PRICE SENSITIVE	140.26KB	Share
NTI Neurotech Receives $10 Million in Placement Funds
24/04/24		83.91KB	Share
NTI Notification regarding unquoted securities - NTI
24/04/24		17.64KB	Share
NTI Secondary Trading Notice
24/04/24		91.73KB	Share
NTI Application for quotation of securities - NTI
24/04/24		15.81KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
23/04/24	PRICE SENSITIVE	445.81KB	Share
NTI Initial Director's Interest Notice
19/04/24		125.34KB	Share
NTI Final Director's Interest Notice
19/04/24		130.37KB	Share
NTI Proposed issue of securities - NTI
19/04/24		16.84KB	Share
NTI Board Changes
19/04/24		102.61KB	Share
NTI Investor Presentation
17/04/24		2.32MB	Share
NTI Proposed issue of securities - NTI
17/04/24		18.84KB	Share
NTI Neurotech Completes $10 Million Capital Raise
17/04/24	PRICE SENSITIVE	193.4KB	Share
NTI Positive Top-Line Rett Syndrome Clinical Trial Results
17/04/24	PRICE SENSITIVE	200.12KB	Share
NTI Phase II/III ASD Trial Successfully Meets Primary Endpoint
17/04/24	PRICE SENSITIVE	361.07KB	Share
NTI Investor Webinar on Clinical Trial Results
16/04/24		98.91KB	Share
NTI Trading Halt
15/04/24	PRICE SENSITIVE	141.44KB	Share
NTI Proposed issue of securities - NTI
10/04/24		19.39KB	Share
NTI Strategic Partnership with Fenix Innovation Group
10/04/24		196.39KB	Share
NTI Last Patient Completes Treatment in NTIASD2 Clinical Trial
10/04/24	PRICE SENSITIVE	183.31KB	Share
NTI Change in substantial holding
27/03/24		289.69KB	Share
NTI Appointment of Joint Company Secretary
21/03/24		76.78KB	Share
NTI Neurotech Presentation at NWR Virtual Healthcare Conference
21/03/24		2.52MB	Share
NTI Neurotech to present at NWR Virtual Healthcare Conference
19/03/24		98.59KB	Share
NTI Secondary Trading Notice
15/03/24		91.99KB	Share
NTI Notification regarding unquoted securities - NTI
15/03/24		14.66KB	Share
NTI Application for quotation of securities - NTI
15/03/24		15.68KB	Share
NTI NTI to Present at Spark Plus Conference in Singapore
13/03/24		2.59MB	Share
NTI Rett Syndrome Patients to Receive NTI164 for 52 Weeks
13/03/24	PRICE SENSITIVE	180.94KB	Share
NTI Notification of cessation of securities - NTI
12/03/24		14.65KB	Share
NTI Secondary Trading Notice
11/03/24		91.98KB	Share
NTI Notification regarding unquoted securities - NTI
08/03/24		14.99KB	Share
NTI Application for quotation of securities - NTI
08/03/24		15.9KB	Share
NTI Initial ESG Report
27/02/24		1.8MB	Share
NTI Appendix 4D and Half Year Accounts
27/02/24	PRICE SENSITIVE	814.41KB	Share
NTI Investor Presentation
21/02/24		2.39MB	Share
NTI PANDAS/PANS Patients Show Continued Clinical Improvement
21/02/24	PRICE SENSITIVE	325.1KB	Share
NTI Secondary Trading Notice
14/02/24		93.56KB	Share
NTI Notification regarding unquoted securities - NTI
14/02/24		14.99KB	Share
NTI Application for quotation of securities - NTI
14/02/24		15.91KB	Share
NTI Neurotech Receives Additional HREC Approval in Autism
13/02/24	PRICE SENSITIVE	114.1KB	Share
NTI ASD Phase I/II Patients Exceed Treatment Beyond 90 Weeks
07/02/24		130.25KB	Share
NTI Amended Change of Director's Interest Notice
30/01/24		233.81KB	Share
NTI Change of Director's Interest Notice
30/01/24		150.24KB	Share
NTI NTI Receives HREC Approval for Cerebral Palsy Trial
29/01/24	PRICE SENSITIVE	179.92KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
24/01/24	PRICE SENSITIVE	583.12KB	Share
NTI Secondary Trading Notice
22/01/24		91.57KB	Share
NTI Application for quotation of securities - NTI
22/01/24		25.64KB	Share
NTI Notification regarding unquoted securities - NTI
17/01/24		28.33KB	Share
NTI Secondary Trading Notice
19/12/23		91.77KB	Share
NTI Application for quotation of securities - NTI
19/12/23		24.91KB	Share
NTI Phase II/III Autism Clinical Trial Completes Recruitment
19/12/23	PRICE SENSITIVE	178.77KB	Share
NTI Change in substantial holding
05/12/23		291.25KB	Share
NTI HREC Approval to Extend Phase II/III ASD Trial to Adults
04/12/23	PRICE SENSITIVE	175.52KB	Share
NTI Change of Director's Interest Notice x 2
01/12/23		329.86KB	Share
NTI Application for quotation of securities - NTI
30/11/23		24.93KB	Share
NTI Investor Presentation
22/11/23		2.34MB	Share
NTI New Constitution
15/11/23		603.29KB	Share
NTI Results of Meeting
15/11/23		103.44KB	Share
NTI 2023 Annual General Meeting Presentation
15/11/23		1.89MB	Share
NTI Chairman's Address to 2023 Annual General Meeting
15/11/23		111.09KB	Share
NTI Neurotech Receives $3.17 Million R&D Tax Incentive Refund
14/11/23	PRICE SENSITIVE	105.98KB	Share
NTI Q&A on Phase I/II PANDAS/PANS Clinical Trial Results
01/11/23		169.14KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
27/10/23	PRICE SENSITIVE	396.35KB	Share
NTI Notice of Quarterly Investor Conference Call
24/10/23		101.25KB	Share
NTI Notice of Annual General Meeting/Proxy Form
16/10/23		626.33KB	Share
NTI Investor Presentation - PANDAS/PANS Clinical Trials Results
06/10/23		1.58MB	Share
NTI Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint
06/10/23	PRICE SENSITIVE	202.18KB	Share
NTI Trading Halt
04/10/23	PRICE SENSITIVE	503.7KB	Share
NTI Completion of Patient Recruitment in NTIRTT1 Clinical Trial
26/09/23	PRICE SENSITIVE	186.34KB	Share
NTI Annual Report (Typeset)
22/09/23		6.67MB	Share
NTI Secondary Trading Notice
18/09/23		93.51KB	Share
NTI Application for quotation of securities - NTI
18/09/23		25.51KB	Share
NTI Proposed issue of securities - NTI
15/09/23		24.56KB	Share
NTI Clinician Briefing Presentation and Webcast
15/09/23		1.78MB	Share
NTI Proposed issue of securities - NTI
15/09/23		31.63KB	Share
NTI Appointment of Corporate Advisor
15/09/23		93.81KB	Share
NTI Upcoming Clinician Briefing
11/09/23		161.9KB	Share
NTI Last Patient Completes Treatment in NTIPANS1 Clinical Trial
31/08/23	PRICE SENSITIVE	141.88KB	Share
NTI Appendix 4G and Corporate Governance Statement
30/08/23		375.23KB	Share
NTI Appendix 4E & Annual Report
30/08/23	PRICE SENSITIVE	1.16MB	Share
NTI Application for quotation of securities - NTI
08/08/23		24.86KB	Share
NTI Proposed issue of securities - NTI
04/08/23		24.68KB	Share
NTI Disclosure Document
04/08/23		310.97KB	Share
NTI First Patient Treated in Rett Syndrome Clinical Trial
01/08/23	PRICE SENSITIVE	181.29KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
26/07/23	PRICE SENSITIVE	321.97KB	Share
NTI Notice of Quarterly Investor Conference Call
19/07/23		138.69KB	Share
NTI NTI Receives HREC Approval for Rett Syndrome Clinical Trial
10/07/23	PRICE SENSITIVE	213.2KB	Share
NTI Notification of cessation of securities - NTI
30/06/23		22.47KB	Share
NTI Notification regarding unquoted securities - NTI
28/06/23		43.13KB	Share
NTI NTI to Present at Rett Syndrome Foundation Meeting
05/06/23		120.49KB	Share
NTI Results of Meeting
01/06/23		102.52KB	Share
NTI NTI Granted 2 Year Extension of Treatment for ASD Patients
31/05/23	PRICE SENSITIVE	188.33KB	Share
NTI NTI granted HREC Approval for PANDAS/PANS Trial Extension
30/05/23	PRICE SENSITIVE	178.8KB	Share

REFRESH

1 2 3 4 5

(20min delay)
Last 5.7¢		Change -0.005(8.06%)		Mkt cap ! $57.99M

Open	High	Low	Value	Volume
6.5¢	6.5¢	5.5¢	$194.8K	3.233M

Buyers (Bids)

No.	Vol.	Price($)
2	22241	5.8¢

Sellers (Offers)

Price($)	Vol.	No.
6.1¢	152989	2

View Market Depth

No.	Vol.	Price($)
2	22241	0.058
4	170363	0.057
1	71719	0.055
1	16745	0.054
1	47909	0.051

Price($)	Vol.	No.
0.061	152989	2
0.063	250000	1
0.064	207847	1
0.065	9876	1
0.069	174000	1

Last trade - 15.59pm 05/06/2024 (20 minute delay)


Last 5.8¢		Change -0.005 ( 7.94 %)
Open	High	Low	Volume
6.4¢	6.4¢	5.7¢	600782
Last updated 15.59pm 05/06/2024 ?

NTI (ASX) Chart

NEUROTECH INTERNATIONAL LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories